CRP-induced activation of immune pathways in SLE patients has been shown to enhance atherosclerotic plaque formation, reduce nitric oxide bioavailability, and promote a pro-thrombotic state [29]. This evidence concerns the gene CRP and systemic lupus erythematosus.